Market Research Future has added a report titled “Mucormycosis Market Research Report-
Global Forecast till 2023” to its offering. The report provides an in-depth analysis of regional
data and an accurate projection of the market size and share of the Top 10 market players
across the globe.
Market Scenario:
Mucormyc osis (zygomycosis) is a serious but rare fungal infection caused by a group of
molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the
lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape,
burn, or other type of skin trauma. There are approximately 1.5 million different species of
fungi on the earth, however, only around 300 are responsible for causing diseases and
infections in humans. Fungal infection may affect anyone, but they are most co mmon in
people with weakened immune systems and can occur in nearly any part of the body. Risk
factors for developing mucormycosis include uncontrolled diabetes, cancer, organ
transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.
Get Premium Copy @ https://www.marketresearchfuture.com/sample_request/5440
These infections need to be treated with prescribed antifungal medication, usually
amphotericin B, posac onazole or isavuconazole. Amphotericin B, posaconazole, and
isavuconazole are medications given intravenously. Furthermore, posaconazole and
isavuconazole can also be administered orally. Often, mucormycosis requires surgery to
remove the infected tissue.
The prognosis of mucormycosis is usually poor. It depends on various factors such as the
overall health of the patient and ability to respond to treatments, the speed of diagnosis,
and treatment provided. For instance, the mortality rate with rhinocerebral and GI
mucormycosis is about 85% while the mortality rate for patients with other types of
mucormycosis is about 50%. Patients who survive this infection often end up having
disabilities such as blindness, limb loss, organ dysfunctions among others.
The market growth is mainly driven by increasing prevalence of fungal infections,
availability of wide range of products, and rising incident of immunological diseases.
Moreover, increasing awareness about fungal infection and increasing government support
for research & development have fuelled the market growth. However, side effects of the
treatment and presence of misbranded and spurious drugs may slow the growth of the
market. There are a number of medicines available in the market for the treatment of fung al
infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions,
and pessaries.
Rising incidence of immunological diseases and availability of a wide range of products has
driven the growth of the global mucormycosis market. Furthermore, rising geriatric
population, increasing government support, and increasing healthcare expenditure have
fueled the growth of the market. However, side effects of the drugs and presence of
misbranded drugs may hinder the growth of the market.
The global market for mucormycosis is expected to grow at a CAGR of
approximately 7.3% during the forecast period, 2017-2023.
Key Players:
The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited
(India), Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La
Roche (Switerzland), Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers
Squibb (U.S.), Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson
& Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others
Segmentation:
The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end -
users.
On the basis of the species, the market is segmented into Rhizopus, Rhizomucor,
Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor,
and others